Post Marketing Study on Pluvicto in Korea
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
Post marketing study on Pluvicto in Korea
Eligibility criteria
Qualifiers
Male adult patient age ≥ 18
Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
Subject who provided the written informed consent prior to the study enrollment
Disqualifiers
Subject whose medical record is not accessible
Subject who is not willing to provide the informed consent
Trial design
Treatments tested in this trial
- Lutetium vipivotide tetraxetan
Treatment groups
278 Participants
are divided into 1 treatment groupLocations
11Novartis Investigative Site13620, Seongnam-siGyeonggi-do, South Korea
Novartis Investigative Site442-723, SuwonGyeonggi-do, South Korea
Novartis Investigative Site46033, BusanKorea, South Korea
Novartis Investigative Site10408, Gyeonggi-doKorea, South Korea
Sponsors and collaborators
Novartis Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov